Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s share price fell 8.4% during mid-day trading on Wednesday . The stock traded as low as GBX 9.80 ($0.13) and last traded at GBX 9.80 ($0.13). 421,339 shares were traded during mid-day trading, a decline of 77% from the average session volume of 1,806,805 shares. The stock had previously closed at GBX 10.70 ($0.14).
Poolbeg Pharma Trading Up 3.9 %
The company’s 50 day moving average is GBX 12.22 and its 200-day moving average is GBX 11.91. The company has a market capitalization of £50.90 million, a P/E ratio of -980.00 and a beta of 2.12.
About Poolbeg Pharma
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Ride Out The Recession With These Dividend Kings
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Why Invest in High-Yield Dividend Stocks?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
